Cargando…
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
PARP inhibitors have been proposed as a potential targeted therapy for patients with triple-negative (ER-, PR-, HER2-negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial. To better understand the mech...
Autores principales: | Bajrami, Ilirjana, Kigozi, Asha, Van Weverwijk, Antoinette, Brough, Rachel, Frankum, Jessica, Lord, Christopher J, Ashworth, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491838/ https://www.ncbi.nlm.nih.gov/pubmed/22933245 http://dx.doi.org/10.1002/emmm.201201250 |
Ejemplares similares
-
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009) -
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity
por: Frankum, Jessica, et al.
Publicado: (2015) -
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021) -
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
por: Pettitt, Stephen J., et al.
Publicado: (2013) -
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)